(VIANEWS) – The NASDAQ opens in less than one hour and Castle Biosciences‘s pre-market value is already 5.12% up.
Castle Biosciences’s last close was $13.25, 63.3% below its 52-week high of $36.10.
The last session, NASDAQ ended with Castle Biosciences (CSTL) jumping 0.53% to $13.25. NASDAQ fell 0.16% to $13,667.29, after two consecutive sessions in a row of losses, on what was a somewhat down trend trading session.
About Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Earnings Per Share
As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.61.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.33%.
Sales Growth
Castle Biosciences’s sales growth is 26.8% for the current quarter and 20.2% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 1416.7% and a negative 27.3%, respectively.
More news about Castle Biosciences (CSTL).
